12/6/2012 10:57:53 AM
BERLIN--(BUSINESS WIRE)--NOXXON Pharma announced its participation at the 54th annual meeting of the American Society of Hematology (ASH) in Atlanta, USA from 8-11 December 2012. Two posters will be presented based on the outcome of two independent Phase I clinical trials which assessed the safety of Spiegelmer® NOX-H94 in a first-in-human study as well as its potential to prevent an inflammation induced drop in serum iron in a human experimental model of endotoxemia. NOX-H94 is a candidate for the treatment of anemia of chronic disease. There will also be two oral presentations on the mode of action of the Spiegelmer® NOX-A12 in two hematological cancers, chronic lymphocytic leukemia (CLL) and multiple myeloma (MM), which were studied in novel experimental settings.
comments powered by